
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine is a promising company with a potential for significant growth in the future. Its pipeline includes several promising candidates targeting various hematologic disorders, and its financials are supported by strong collaboration and other revenue. However, there are risks associated with regulatory approval, commercialization, and financial viability, which may affect its success. The upcoming FDA meeting to discuss selcodebart as a potential treatment for myelofibrosis-associated anemia is a key development to watch for and could be a major value inflection point for the company.
Bears say
Disc Medicine is facing high clinical trial risk with the potential for failure of its pipeline candidates, including DISC-3405 and DISC-0974. The company's financials are heavily reliant on the success of its pipeline, and its valuation is not supported by current sales or projected sales in the near future. Additionally, the limited clinical data available for the company's candidates leaves room for uncertainty and further downside potential.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares